Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion non-small cell lung cancer (NSCLC).

9065Background: Selpercatinib, a first-in-class highly selective and potent, CNS-active RET kinase inhibitor, is approved in multiple countries for treatment of RET fusion+ lung or thyroid cancers....